Verastem Inc
VSTM
Company Profile
Business description
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Contact
117 Kendrick Street
Suite 500
NeedhamMA02494
USAT: +1 781 292-4200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
102
Stocks News & Analysis
stocks
The SpaceX IPO and the Elon Musk factor
Potential investors should remember that the company’s controlling shareholder can move markets with a few words.
stocks
The ASX’s most shorted stocks in 2026
What we can and can’t learn from the top 20 most shorted ASX shares.
stocks
ASX energy producers: Energy prices rise sharply as global tensions flare, but long-term view unchanged
Our view on the chaotic energy markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,657.50 | 2.20 | 0.03% |
| CAC 40 | 7,701.95 | 67.36 | -0.87% |
| DAX 40 | 22,300.75 | 312.22 | -1.38% |
| Dow JONES (US) | 45,165.80 | 794.31 | -1.73% |
| FTSE 100 | 9,967.35 | 4.82 | -0.05% |
| HKSE | 24,684.82 | 267.06 | -1.07% |
| NASDAQ | 20,948.36 | 459.72 | -2.15% |
| Nikkei 225 | 51,727.72 | 1,645.35 | -3.08% |
| NZX 50 Index | 12,748.92 | 186.47 | -1.44% |
| S&P 500 | 6,370.69 | 106.47 | -1.64% |
| S&P/ASX 200 | 8,461.00 | 0.10 | 0.00% |
| SSE Composite Index | 3,921.10 | 7.38 | 0.19% |